Search

everythinglearnresearchcommunity

for

Search:↓

COVID-19 can lead to different skin symptoms and might trigger autoimmune diseases in genetically susceptible people.

A child with a rare vitamin D-resistant condition improved with treatment.

A girl with a rare genetic disorder had a unique bone condition, highlighting the need for careful diagnosis and suggesting the disorder might be more common than thought.

Different types of Armillaria fungus have a high genetic variety when partnering with Polyporus umbellatus mushrooms in China.

An 87-year-old man showed unusual signs of Hodgkin lymphoma, primarily high calcium levels, which improved after treatment and revealed the disease.

Not getting enough minerals can lead to health problems and shorter lifespans.

The article concludes that proper injection techniques and patient education can prevent serious skin reactions from multiple sclerosis medications.

The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.

Birt–Hogg–Dubé Syndrome requires genetic testing for accurate diagnosis due to its similarities with tuberous sclerosis.

Dimethyl-fumarate may cause temporary hair loss.

Two patients developed complete hair loss after Alemtuzumab treatment for MS, with no regrowth after two years.

A woman with lupus and systemic sclerosis developed severe acne that didn't improve with treatment and died from pneumonia and septic shock.

A high fat lard diet may protect against skin fibrosis and affect hair growth.

Interferon beta treatment in MS patients can cause skin reactions and increased hair loss.

Some multiple sclerosis treatments may trigger hair loss conditions like alopecia areata.

Skin tumor cells in patients with tuberous sclerosis have higher levels of a protein called cathepsin B.

Most patients with Tuberous sclerosis had neurological or skin issues, and over half had psychiatric problems.

Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.

Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.

Hair thinning is a common but generally mild and reversible side effect of teriflunomide in multiple sclerosis patients.

A comprehensive approach to educating patients and managing side effects is crucial for improving adherence to multiple sclerosis treatments and patient quality of life.

Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.

Chaga mushrooms contain compounds that may promote hair growth better than common treatments.

New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.

Blood vessel patterns in skin diseases relate to certain blood markers in systemic sclerosis but not in psoriasis or psoriatic arthritis, and may indicate circulation issues in alopecia.

Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.

Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.

Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.

Post-void residual volume does not predict worsening urological symptoms in multiple sclerosis patients.

EPDS and MS might share an immune-related cause.